LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Kura Oncology Inc

Cerrado

SectorSalud

5.7 -2.06

Resumen

Variación precio

24h

Actual

Mínimo

5.67

Máximo

5.73

Métricas clave

By Trading Economics

Ingresos

-38M

-57M

Ventas

-40M

14M

BPA

-0.66

Margen de beneficio

-407.067

Empleados

192

EBITDA

-48M

-65M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+323.88% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-38M

488M

Apertura anterior

7.76

Cierre anterior

5.7

Noticias sobre sentimiento de mercado

By Acuity

22%

78%

54 / 381 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Kura Oncology Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

30 may 2025, 23:51 UTC

Adquisiciones, fusiones, absorciones

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 may 2025, 21:30 UTC

Principales Noticias

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 may 2025, 21:15 UTC

Principales Noticias

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 may 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

30 may 2025, 20:44 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 may 2025, 20:24 UTC

Principales Noticias

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 may 2025, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

30 may 2025, 19:44 UTC

Charlas de Mercado

Gold Breaks 4-Month Winning Streak -- Market Talk

30 may 2025, 19:38 UTC

Charlas de Mercado

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 may 2025, 19:29 UTC

Ganancias
Adquisiciones, fusiones, absorciones

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 may 2025, 19:14 UTC

Charlas de Mercado

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 may 2025, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 may 2025, 18:51 UTC

Charlas de Mercado

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 may 2025, 18:37 UTC

Charlas de Mercado
Ganancias

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 may 2025, 18:04 UTC

Principales Noticias

S&P 500 Falls After More Trump-China Friction -- WSJ

30 may 2025, 17:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 may 2025, 17:47 UTC

Charlas de Mercado

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 may 2025, 17:40 UTC

Adquisiciones, fusiones, absorciones

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 may 2025, 17:38 UTC

Charlas de Mercado

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 may 2025, 17:31 UTC

Charlas de Mercado

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 may 2025, 17:14 UTC

Principales Noticias

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30 may 2025, 16:31 UTC

Ganancias

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30 may 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

30 may 2025, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

30 may 2025, 16:16 UTC

Principales Noticias

S&P 500 Falls After Trump Hits Out at China -- WSJ

30 may 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

30 may 2025, 16:14 UTC

Principales Noticias

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

30 may 2025, 16:12 UTC

Charlas de Mercado

Base Metal Prices Slide on Stronger Dollar But Copper Shortage Fears Remain -- Market Talk

30 may 2025, 16:02 UTC

Charlas de Mercado

Latest Twists in U.S. Tariff Saga Being Digested by Commodity Markets -- Market Talk

30 may 2025, 15:31 UTC

Principales Noticias

Judge Considers Curbs for Google in AI Arms Race -- Update

Comparación entre iguales

Cambio de precio

Kura Oncology Inc Esperado

Precio Objetivo

By TipRanks

323.88% repunte

Estimación a 12 meses

Media 24.67 USD  323.88%

Máximo 40 USD

Mínimo 10 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

11

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

5.575 / 6.6Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

54 / 381 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.